Lepodisiran vs SYH2068
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: LPA gene / apolipoprotein(a) mRNA · full Atherosclerotic Cardiovascular Disease pipeline
Lepodisiran
Developed by Eli Lilly and partners
NCT05565742 · Phase 2 · completed
The trial randomized 320 participants and used double blinding with a placebo control. Its primary endpoint was a statistically significant reduction in Lp(a) versus placebo for all doses, but Lp(a) is a laboratory biomarker rather than a direct clinical outcome, so the findings provide moderate evidence.
Next expected readout: March 2027 · NCT07914738 (registry estimate)
Reported efficacy
Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo) (met)
Result source: NCT05565742
SYH2068
Developed by CSPC Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2028 · NCT07640217 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lepodisiran | SYH2068 |
|---|---|---|
| LDL-C, % change | —Trial running · NCT06292013 | —Not reported |
| Non-HDL-C, % change | —Trial running · NCT06292013 | —Not reported |
| ApoB, % change | -9.1% vs 4.3%−13.4 vs placeboNCT0556574219 other results
| —Not reported |
| Lp(a), % change | -74.4% vs 3.1%−77.5 vs placeboNCT0556574225 other results
| —Not reported |
| 3-point MACE (% with event) | —Trial running · NCT06292013 | —Not reported |
LDL-C, % change
- Lepodisiran
- —Trial running · NCT06292013
- SYH2068
- —Not reported
Non-HDL-C, % change
- Lepodisiran
- —Trial running · NCT06292013
- SYH2068
- —Not reported
ApoB, % change
- Lepodisiran
- -9.1% vs 4.3%−13.4 vs placeboNCT05565742
19 other results
- -0.9% vs 4.3% NCT05565742
- -10.4% vs 4.3% NCT05565742
- -4.6% vs 4.3% NCT05565742
- -14% vs 1.8% NCT05565742
- -9% vs 1.8% NCT05565742
- -12.6% vs 1.3% NCT05565742
- -12.6% vs 1.3% NCT05565742
- -13.9% vs 0.2% NCT05565742
- -13.9% vs 0.2% NCT05565742
- -0.6% vs 4.3% NCT05565742
- -8.1% vs 4.3% NCT05565742
- -13.8% vs 1.8% NCT05565742
- -9.6% vs 1.3% NCT05565742
- -11.8% vs 0.2% NCT05565742
- 1.4% vs 4.3% NCT05565742
- -2.9% vs 4.3% NCT05565742
- -7.6% vs 1.8% NCT05565742
- -7% vs 1.3% NCT05565742
- -10.2% vs 0.2% NCT05565742
- SYH2068
- —Not reported
Lp(a), % change
- Lepodisiran
- -74.4% vs 3.1%−77.5 vs placeboNCT05565742
25 other results
- -39% vs 3.1% NCT05565742
- -73.8% vs 1.3% NCT05565742
- -52.8% vs 1.3% NCT05565742
- -91.1% vs -0.9% NCT05565742
- -68.1% vs -0.9% NCT05565742
- -96.8% vs -0.8% NCT05565742
- -84.9% vs -0.8% NCT05565742
- -90.5% vs 2.2% NCT05565742
- -90.5% vs 2.2% NCT05565742
- -95.4% vs 2.2% NCT05565742
- -95.4% vs 2.2% NCT05565742
- -95% vs 0.3% NCT05565742
- -76.7% vs 0.3% NCT05565742
- -45.1% vs 1.3% NCT05565742
- -67.7% vs -0.9% NCT05565742
- -84.8% vs -0.8% NCT05565742
- -65.3% vs 2.2% NCT05565742
- -80.4% vs 2.2% NCT05565742
- -77.4% vs 0.3% NCT05565742
- -18.7% vs 1.3% NCT05565742
- -30.8% vs -0.9% NCT05565742
- -47.7% vs -0.8% NCT05565742
- -30.5% vs 2.2% NCT05565742
- -46.2% vs 2.2% NCT05565742
- -38.7% vs 0.3% NCT05565742
- SYH2068
- —Not reported
3-point MACE (% with event)
- Lepodisiran
- —Trial running · NCT06292013
- SYH2068
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SYH2068: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lepodisiran: 3 of 4 rows · SYH2068: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lepodisiran |
|---|---|
| Dropout rate | 2.9%400 mga NCT05565742 · Phase 2 show 3 more results2.8%400 mg NCT05565742 · Phase 2 0%96 mg NCT05565742 · Phase 2 2.8%16 mg NCT05565742 · Phase 2 |
| Discontinued due to AEs | —400 mga NCT05565742 · Phase 2 show 3 more results—400 mg NCT05565742 · Phase 2 —96 mg NCT05565742 · Phase 2 —16 mg NCT05565742 · Phase 2 |
| Serious AEs | 15.9%400 mga NCT05565742 · Phase 2 show 3 more results11.1%400 mg NCT05565742 · Phase 2 12.2%96 mg NCT05565742 · Phase 2 2.8%16 mg NCT05565742 · Phase 2 |
| Most frequent reported AEs | 400 mga injection site reaction 11.6% (placebo 1.4%) covid-19 7.2% (placebo 10.1%) nasopharyngitis 7.2% (placebo 8.7%) NCT05565742 · Phase 2 show 3 more results400 mg nasopharyngitis 13.9% (placebo 8.7%) arthralgia 8.3% (placebo 2.9%) injection site reaction 8.3% (placebo 1.4%) NCT05565742 · Phase 2 96 mg influenza 9.5% (placebo 2.9%) injection site reaction 8.1% (placebo 1.4%) nasopharyngitis 8.1% (placebo 8.7%) NCT05565742 · Phase 2 16 mg influenza 11.1% (placebo 2.9%) ovarian cyst 11.1% (placebo 0%) covid-19 5.6% (placebo 10.1%) NCT05565742 · Phase 2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lepodisiran
show 25 more results
show 19 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lepodisiran's landscape · SYH2068's landscape